Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters
This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Source
Radiology Business
Related News
•Health Imaging
AI Detects Incidental Lung Nodules on Routine Chest X-Rays
AI can identify pulmonary nodules on chest X-rays, aiding early lung cancer detection even when scans are not respiratory-related.
•AuntMinnie
How Agentic AI Is Transforming Imaging Interoperability
Agentic AI can automate complex, non-standard tasks in imaging interoperability, reducing manual work and improving efficiency.
•AuntMinnie
AI in Breast Imaging Achieves High NPV but Raises Recall Rates
AI systems in breast imaging yield near-perfect negative predictive value but increase recall rates compared to radiologists, particularly for intermediate-risk classifications.